Compare Coinbase Global, Inc. (COIN) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

COIN trades at $179.39, up 0.53% today, with a bullish technical signal despite recent earnings misses. Revenue grew to $7.18B in 2025, but net income margin turned negative at -15.72%. The company maintains strong cash flow from operations at $2.43B and holds $9.55B in cash. Recent CFTC approval for derivatives clearing and expanded Citigroup partnership signal strategic expansion.

Outlook remains mixed with 55% analyst buy ratings and a $211.91 price target, but negative profitability and projected 2026 net loss of -$988M pose significant risks. Stock performance hinges on execution in derivatives and stablecoin initiatives amid volatile crypto markets.

Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.

The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.